Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that its Annual Report and Accounts for the year ended 31 December 2020 and the Notice of the 2021 Annual General Meeting are now available on the Company’s website, www.avacta.com.
Copies of the Annual Report and Accounts and the Notice of AGM have been posted to shareholders who have elected to receive them in paper form.
The Annual General Meeting will be held on Monday, 28 June 2021 at 10.00 a.m. at the offices of Walker Morris LLP at 33 Wellington Street, Leeds LS1 4DL.
In the light of the Coronavirus pandemic, shareholders are strongly urged to appoint the chairman of the Meeting as his or her proxy as, given the Coronavirus situation and current Government advice on public gatherings, attendance in person is not advised.
To enable shareholders to raise any questions they may have prior to the AGM, the Company will be providing a Business Update webinar led by Alastair Smith, Chief Executive Officer which will take place at 10:00am on Monday 21 June 2021.
The webinar is open to all shareholders and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Shareholders can sign up to Investor Meet Company for free and then click “Add to meet” Avacta Group via the following link to join the webinar:
Shareholders who already follow Avacta Group plc on the Investor Meet Company platform will automatically be invited.